Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial.

Interestingly, the proliferative ability of zamto-cel as assessed by CD27 and CD127/IL-7R expression showed a trend for increased expression in patients with CR (CAR + CD4 + CD27 + in CR [mean, 86.2; 95% CI, 73.57-91.59] vs non-CR [mean, 60.98; 95% CI, 8.93-92.14; P = .14], CAR + CD4 + CD127/IL-7R + in CR [mean, 82.09; 95% CI, 76.97-88.93] vs non-CR [mean, 59.34; 95% CI, 29.87-82.48; P = .035], CAR + CD8 + CD27 + in CR [mean, 88.85; 95% CI, 82.09-94.46] vs non-CR [mean, 66.33; 95% CI, 16.55-94.01; P = .05] and CAR + CD8 + CD127/IL-7R + in CR [mean, 26.72; 95% CI, 15.52-43.95] vs non-CR [mean, 12.36; 95% CI, 1.93-49.96; P = .1]; Figure 3 A-B; supplemental Figure 6 C).

also in 53,322 other papers